How Long Can You Live With Untreated Prostate Cancer?

How long you can live with untreated prostate cancer depends almost entirely on the tumor’s grade and how old you are when it is found. A man diagnosed with a low-grade tumor in his mid-sixties may lose no life expectancy at all compared to the general population, while a man with a high-grade tumor can face a median disease-specific survival of less than five years without treatment. That range is enormous, and it is the reason conversations about prostate cancer so often include the phrase “it depends.” The biology of this cancer is unusually variable, and the factors that separate an indolent tumor from a lethal one are worth understanding in some detail.

Tumor Grade Is the Single Biggest Predictor

Prostate cancer is graded using the Gleason scoring system, which assigns a number based on how abnormal the cells look under a microscope. The scores range from 6 (low grade, well-differentiated cells) up to 10 (high grade, poorly differentiated). That number does more to predict your outcome than almost anything else. A large population-based study found that men with the lowest-grade tumors (Gleason 6 or less) had a ten-year cancer-specific survival rate above 98%, while men with Gleason 8 to 10 disease had a rate around 70%.¹ A twenty-year Swedish follow-up put it even more starkly: given a Gleason score of 8 or higher, the probability of eventually dying from prostate cancer was close to half.²

The middle of the grading scale matters too, and not all Gleason 7 tumors are equal. When the dominant pattern is the less aggressive one (scored as 3+4), ten-year cancer-specific survival is around 92%. Flip that pattern to 4+3, where the more aggressive component predominates, and survival drops to roughly 77%.¹ That gap is large enough that clinicians now treat these as distinct risk categories.

Low-Grade Tumors and Life Expectancy

For men with low-grade prostate cancer who choose conservative management, the long-term data are surprisingly reassuring. A study following men for an average of 15.5 years found that those with the lowest-grade tumors (Gleason 2 to 4) had survival that was statistically indistinguishable from men of the same age without prostate cancer.³ Even men with Gleason 5 to 7 tumors lost an estimated four to five years of life expectancy, while those with the highest grades lost six to eight years.

A Swedish prospective study followed 223 men with localized prostate cancer on deferred treatment (no initial surgery or radiation) and found a corrected 15-year survival rate of 81%. Only about 11% of men with localized disease in the full cohort died of prostate cancer during that period, and outcomes were similar whether men received early treatment or watchful waiting.⁴ Extended follow-up of that same Swedish cohort out to 32 years showed that 17% of the men ultimately died from their prostate cancer, with cause-specific survival declining mostly between years 15 and 20 before stabilizing.⁵

A comprehensive review pooling 15 major studies and more than 43,000 patients confirmed the overall pattern: Grade Group 1 tumors carried less than a 5% risk of developing metastases over 15 to 20 years.⁶ For many men, a low-grade prostate cancer found in their sixties or seventies will never become the thing that kills them.

High-Grade Tumors Tell a Very Different Story

The picture changes dramatically at the upper end of the grading scale. That same comprehensive review found that Grade Groups 4 and 5 (roughly Gleason 8 to 10) exhibited rapid progression, with a median disease-specific survival of less than five years without curative treatment.⁶ These tumors are more likely to spread to bone and lymph nodes, and once metastatic, the disease becomes manageable but generally not curable.

The timeline from local recurrence to metastasis is also shaped by how fast PSA levels rise. In men who had surgery and later experienced a PSA recurrence, the median time to developing visible metastases ranged from as short as one year to as long as 15 years, depending on both the Gleason score and the PSA doubling time.⁷ A fast doubling time, particularly under three months, signals aggressive biology and a shorter window before the cancer spreads.

Why Many Men With Prostate Cancer Die of Something Else

One of the most important and often overlooked realities of prostate cancer is that the majority of men diagnosed with it will die from an unrelated cause. This is especially true for men who are older at diagnosis or who have other serious health conditions. A study using U.S. population data found that among men with low-risk prostate cancer, only about 3% died from their cancer over 14 years, while men with one or more additional health conditions (heart disease, diabetes, chronic lung disease, and similar) had dramatically higher rates of death from those other problems.⁸

Another analysis found that at ten years after diagnosis, men with the highest burden of other illnesses (a comorbidity score of 3 or more) had a 74% rate of dying from something other than prostate cancer. Meanwhile, prostate cancer mortality itself remained rare in the low-risk and intermediate-risk groups: under 1% and 3%, respectively.⁹ The practical takeaway: if you are in your late seventies with diabetes, heart disease, and another chronic condition, a low-grade prostate cancer is very unlikely to be what shortens your life.

Men diagnosed after age 75 face roughly 57 to 60% ten-year non-cancer mortality regardless of tumor grade.⁶ This is why treatment decisions in older men weigh the side effects of surgery or radiation so heavily against a cancer that may never become symptomatic during the patient’s remaining lifetime.

Most Prostate Cancer Goes Undiagnosed and Causes No Harm

Autopsy studies reveal something striking about the true prevalence of prostate cancer in the population. A systematic review of autopsy data found that the average prevalence of incidental (undiagnosed) prostate cancer increased in a nonlinear fashion with age, reaching roughly 59% in men over 79.¹⁰ In other words, the majority of men who reach very old age have prostate cancer cells that never caused them a single symptom and were never detected.

Racial differences in this hidden reservoir of cancer are substantial. Among men aged 70 to 79, autopsy-detected prostate cancer was found in roughly half of Black men compared to about 36% of white men and 21% of Asian men. Researchers estimate that among men in their seventies, more than a third of white men and half of Black men harbor indolent prostate cancer that would cause no harm if left alone.¹¹ This enormous gap between cancer that exists in the body and cancer that actually threatens life is central to understanding why “untreated prostate cancer” can mean such different things depending on the tumor.

What the Largest Clinical Trials Show About Skipping Treatment

The most rigorous evidence comparing treatment to observation comes from the PIVOT trial, which randomized men with localized prostate cancer to either surgery or observation and followed them for more than two decades. After roughly 22 years, the surgery group had a modest survival advantage: a mean of about one extra year of life gained, with an absolute mortality difference of around 5.7 percentage points.¹²

The breakdown by risk group was revealing. For men with low-risk disease, the difference between surgery and observation was negligible, less than one percentage point. The benefit of surgery appeared concentrated in intermediate-risk disease, where the absolute difference was about 14.5 percentage points. For high-risk disease, the difference was only about two percentage points, though this may reflect how aggressive cancers tend to become hard to cure regardless of initial approach.¹³ Prostate cancer-specific death was uncommon in the observation arm overall, occurring in about 11% of men assigned to observation compared to about 7% who had surgery.

Active Surveillance Is Not the Same as No Treatment

A distinction that gets lost in public conversation is the difference between active surveillance and truly untreated cancer. Active surveillance means the cancer is monitored with regular PSA tests, imaging, and repeat biopsies, with the plan of offering curative treatment if the cancer shows signs of becoming more aggressive. Watchful waiting is more hands-off, typically used for older men, and aims to manage symptoms if they arise rather than cure the cancer.

Modeling studies comparing these approaches estimate that active surveillance reduces the lifetime risk of dying from prostate cancer (about 5.4%) compared to watchful waiting (about 8.7%), with a corresponding drop in metastasis risk from about 10% to about 6%.¹⁴ For younger men (under 65 at diagnosis), active surveillance was clearly favored. For older men, the calculus shifted because they were less likely to live long enough to benefit from the delayed treatment option, and the side effects of treatment weighed more heavily.

The 15-Year Inflection Point

One pattern that emerges repeatedly in long-term studies is that prostate cancer risk does not stay flat over time, even for low-grade tumors. Across all risk groups, disease progression accelerates after about 15 years from diagnosis.⁶ This is a finding that complicates simple reassurance for younger men. If you are diagnosed at 55 with a low-grade tumor, those 15 years land you at 70, and the annual risk of dying from that cancer continues to climb past that point and peaks after age 85.¹⁵

The 32-year Swedish follow-up captured this pattern clearly: cause-specific survival dropped between years 15 and 20, then plateaued. By the end of follow-up, about 18% of the originally localized cancers had progressed to distant metastasis and 17% of the men had died from the disease.⁵ For a man diagnosed at 75, this late acceleration rarely matters because other causes of death intervene. For a man diagnosed at 55, it is a real consideration that weighs against purely passive observation.

Genetic Factors and Grade Reclassification

Some men carry inherited mutations that make their prostate cancer behave more aggressively than the initial biopsy suggests. The most studied of these are mutations in BRCA2, a gene better known for its role in breast and ovarian cancer. Among men on active surveillance, carriers of BRCA2 mutations had roughly 2.7 times the risk of being reclassified to a higher grade on subsequent biopsy compared to non-carriers.¹⁶ This means a cancer that initially looks low-grade may actually be harboring more aggressive biology that the first biopsy missed.

For men with a known family history of BRCA2 mutations or other DNA-repair gene mutations, the threshold for choosing treatment over surveillance tends to be lower. The cancer may look indolent at first, but the underlying genetic instability gives it a higher probability of upgrading and progressing.

Histological Variants That Change the Timeline

Beyond the Gleason score, certain microscopic patterns within a prostate tumor carry independent prognostic weight. Intraductal carcinoma of the prostate is one that has drawn increasing attention. A meta-analysis found that its presence was associated with roughly triple the hazard of dying from prostate cancer compared to cases without it.¹⁷ When both intraductal carcinoma and an invasive cribriform growth pattern were present at diagnostic biopsy, the hazard of disease-specific death rose roughly elevenfold.¹⁸

These patterns are not always reported separately on pathology reports, and not all pathologists flag them consistently. But emerging evidence links intraductal carcinoma with aggressive disease across all stages of prostate cancer.¹⁹ If your pathology report mentions either of these findings, it is worth a careful conversation about whether observation is still appropriate regardless of the overall Gleason score.

Racial Disparities in Untreated Prostate Cancer

Race significantly affects prostate cancer outcomes even after adjusting for tumor characteristics and treatment. A large analysis found that Black men had worse overall survival than white men with localized prostate cancer, with a risk-adjusted hazard ratio of 1.37 after accounting for primary treatment. Asian men, by contrast, fared better than white men, with a hazard ratio of 0.79.²⁰ These gaps persist after controlling for treatment modality, which means they are not simply explained by differences in access to surgery or radiation.

Some of this disparity reflects biological differences in tumor behavior, and some reflects systemic inequities in healthcare access, screening patterns, and the timing of diagnosis. For Black men weighing observation against treatment, the data suggest a somewhat less forgiving natural history, which may tip the balance toward earlier intervention.

Quality of Life Without Treatment

The strongest argument for avoiding surgery or radiation, at least initially, is quality of life. A systematic review of long-term quality-of-life studies found that men on active surveillance reported overall well-being comparable to men without any cancer diagnosis. Compared to men who had surgery or radiation, men on surveillance had better sexual function and fewer urinary symptoms.²¹

A cohort study comparing active surveillance to surgery found that men avoiding treatment had meaningfully better sexual function scores and much lower rates of incontinence pad use. General quality of life and mental health scores were similar between the groups.²² The tradeoff is that surveillance involves the psychological weight of repeated testing and living with a known but untreated cancer, which some men find manageable and others find deeply stressful.²³

PSA Doubling Time as a Warning Signal

For men who are being monitored rather than treated, the speed at which PSA levels rise over time serves as an important gauge of how aggressively the cancer is behaving. Studies of men with castration-resistant prostate cancer (a more advanced stage) found that those with a PSA doubling time of nine months or longer had roughly half the hazard of dying from their cancer compared to those whose PSA doubled faster.²⁴ In men with very fast doubling times (under three months), prostate cancer was the predominant cause of death regardless of age or other health conditions.

Multivariate analyses have confirmed that pretreatment PSA doubling time is an independent predictor of overall survival across localized, locally advanced, and metastatic disease.²⁵ There is a caveat, though: in men who have not yet had treatment and whose prostate is intact, PSA velocity is a less reliable tool for guiding biopsy decisions or active surveillance eligibility. Its prognostic value is clearest once the cancer has declared itself through a rising PSA after initial treatment or in more advanced disease settings.²⁶

1
PubMed Central. Prostate cancer specific mortality and Gleason 7 disease differences in prostate cancer outcomes between cases with Gleason 4 + 3 and Gleason 3 + 4 tumors in a population based cohort
2
PubMed. How well does the Gleason score predict prostate cancer death? A 20-year followup of a population based cohort in Sweden
3
JAMA. Long-term Survival Among Men With Conservatively Treated Localized Prostate Cancer
4
JAMA. Fifteen-Year Survival in Prostate Cancer: A Prospective, Population-Based Study in Sweden
5
PubMed. Natural history of early, localized prostate cancer: a final report from three decades of follow-up
6
Prostate Cancer and Prostatic Diseases. Natural history of untreated prostate cancer: a comprehensive review of long-term progression patterns and survival outcomes
7
PubMed Central. The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up
8
PubMed Central. Effect of Age, Tumor Risk, and Comorbidity on Competing Risks for Survival in a U.S. Population–Based Cohort of Men With Prostate Cancer
9
PubMed. Comorbidity and competing risks for mortality in men with prostate cancer
10
PubMed Central. Prevalence of incidental prostate cancer: A systematic review of autopsy studies
11
PubMed Central. The High Prevalence of Undiagnosed Prostate Cancer at Autopsy: Implications for Epidemiology and Treatment of Prostate Cancer in the Prostate-Specific Antigen-Era
12
PubMed. Radical Prostatectomy or Observation for Clinically Localized Prostate Cancer: Extended Follow-up of the Prostate Cancer Intervention Versus Observation Trial (PIVOT)
13
PubMed. Follow-up of Prostatectomy versus Observation for Early Prostate Cancer
14
PubMed Central. Active Surveillance Versus Watchful Waiting for Localized Prostate Cancer: A Model to Inform Decisions
15
PubMed Central. The Effect of Age on Prostate Cancer Survival
16
PubMed Central. Germline Mutations in ATM and BRCA1/2 Are Associated with Grade Reclassification in Men on Active Surveillance for Prostate Cancer
17
PubMed. The Prognostic Impact of Intraductal Carcinoma of the Prostate: A Systematic Review and Meta-Analysis
18
Modern Pathology. Disease-specific survival of patients with invasive cribriform and intraductal prostate cancer at diagnostic biopsy
19
PubMed Central. Clinical Management of Intraductal Carcinoma of the Prostate
20
Mayo Clinic Proceedings. Racial Disparities in Survival for Patients With Clinically Localized Prostate Cancer Adjusted for Treatment Effects
21
PubMed Central. Long-term Health-related Quality of Life in Patients on Active Surveillance for Prostate Cancer: A Systematic Review
22
Prostate Cancer and Prostatic Diseases. Quality of life in low-risk prostate cancer under active surveillance or following radical treatments: the START cohort study
23
International Health Sciences Review. Localized prostate cancer: Active surveillance compared with radical treatment and quality of life
24
Prostate Cancer and Prostatic Diseases. Impact of age, comorbidity, and PSA doubling time on long-term competing risks for mortality among men with non-metastatic castration-resistant prostate cancer
25
Oncoscience. Pretreatment prostate specific antigen doubling time as prognostic factor in prostate cancer patients
26
PubMed Central. PSA Velocity and Doubling Time in Diagnosis and Prognosis of Prostate Cancer